SAN FRANCISCO, November 20, 2026 — Hims & Hers Health launched its Peptides+ longevity treatment platform across the United States on Wednesday, marking a major expansion of the telehealth company’s direct-to-consumer subscription model. The rollout brings compounded peptide and nutrient therapies to a national audience through the firm’s existing telehealth infrastructure.
The Offering
The Peptides+ platform includes compounded peptide and nutrient therapies such as sermorelin, NAD+, glutathione, vitamin B-12, and L-carnitine. The program is structured as a personalized service featuring at-home blood collection and ongoing clinical oversight for patients using the therapies.
By the Numbers
Hims & Hers carries a market capitalization of more than $3.5 billion. Synthetic peptides are a broad category of short-chain amino acids initially popular among bodybuilders that have since gained traction among a wider demographic seeking to optimize health, build muscle, increase energy, boost libido, or recover from injuries.
Regulatory Context
Many compounded peptides marketed to consumers are experimental and have not been approved by the Food and Drug Administration, nor are there randomized controlled trials demonstrating their safety and efficacy in humans. The Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., has foregrounded the drug class; Kennedy is described as an avowed peptide enthusiast.
Industry Landscape
The launch coincides with a similar move by Noom, a private company valued at $3.7 billion, signaling a pivotal moment for peptide therapies entering the mainstream U.S. market. While smaller telehealth outfits have offered peptide prescriptions for some time, the entry of two dominant players shifts the competitive dynamics for digital health and wellness subscriptions.
What Investors Will Note
The Peptides+ rollout reinforces the narrative that Hims & Hers growth depends on layering higher-complexity, recurring specialties onto its telehealth and lab infrastructure. The catalyst around peptide-based therapies and at-home diagnostics sits alongside flagged risks, including legal scrutiny and a business mix that can pressure margins. Analysts tracking the stock point to a $28.85 fair value estimate as a reference for judging traction.
Sources
- Peptide market poised to explode with new Hims and Noom launches
- Hims & Hers Health (HIMS) Launches Peptides+ Longevity Platform Across The U.S.
Photo: National Cancer Institute / Unsplash (Unsplash License)





